Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Condom HIV Protection Supported By Panel, Other STDs Inconclusive

This article was originally published in The Tan Sheet

Executive Summary

Latex condom use lowers the risk of acquiring HIV and gonorrhea, but study data on condoms' effectiveness at reducing the risk of other sexually transmitted diseases is inconclusive, according to a recent National Institutes of Health report.

You may also be interested in...



Condoms labeling

"It is critically important that FDA inform consumers that condoms do not provide effective protection against infection that can cause cervical cancer as required by law," Rep. Mark Souder (R-Ind.) maintains in a letter inviting FDA, NCI, CDC and Centers for Medicare & Medicaid Services to a Jan. 28 House Government Reform/Human Resources Subcommittee hearing. Indiana Republican points to a 2001 report by the National Institute of Allergy & Infectious Diseases showing "evidence is currently insufficient" to assess condom use for prevention of HPV, among other STDs (1"The Tan Sheet" July 23, 2001, p. 13). Souder's letter notes that Public Law 106-554, enacted in 2000, mandates that FDA "reexamine existing condom labels...to determine whether the labels are medically accurate regarding the overall effectiveness or lack of effectiveness in preventing sexually transmitted diseases, including HPV." Hearing is slated for 10 a.m. in Room 2154, Rayburn House Office Building...

Condoms labeling

"It is critically important that FDA inform consumers that condoms do not provide effective protection against infection that can cause cervical cancer as required by law," Rep. Mark Souder (R-Ind.) maintains in a letter inviting FDA, NCI, CDC and Centers for Medicare & Medicaid Services to a Jan. 28 House Government Reform/Human Resources Subcommittee hearing. Indiana Republican points to a 2001 report by the National Institute of Allergy & Infectious Diseases showing "evidence is currently insufficient" to assess condom use for prevention of HPV, among other STDs (1"The Tan Sheet" July 23, 2001, p. 13). Souder's letter notes that Public Law 106-554, enacted in 2000, mandates that FDA "reexamine existing condom labels...to determine whether the labels are medically accurate regarding the overall effectiveness or lack of effectiveness in preventing sexually transmitted diseases, including HPV." Hearing is slated for 10 a.m. in Room 2154, Rayburn House Office Building...

Condoms labeling

"It is critically important that FDA inform consumers that condoms do not provide effective protection against infection that can cause cervical cancer as required by law," Rep. Mark Souder (R-Ind.) maintains in a letter inviting FDA, NCI, CDC and Centers for Medicare & Medicaid Services to a Jan. 28 House Government Reform/Human Resources Subcommittee hearing. Indiana Republican points to a 2001 report by the National Institute of Allergy & Infectious Diseases showing "evidence is currently insufficient" to assess condom use for prevention of HPV, among other STDs (1"The Tan Sheet" July 23, 2001, p. 13). Souder's letter notes that Public Law 106-554, enacted in 2000, mandates that FDA "reexamine existing condom labels...to determine whether the labels are medically accurate regarding the overall effectiveness or lack of effectiveness in preventing sexually transmitted diseases, including HPV." Hearing is slated for 10 a.m. in Room 2154, Rayburn House Office Building...

Related Content

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel